Tags

Type your tag names separated by a space and hit enter

Commentary on recent therapeutic guidelines for osteoarthritis.

Abstract

BACKGROUND

Despite availability of international evidence-based guidelines for osteoarthritis (OA) management, agreement on the different treatment modalities is lacking.

METHOD

A symposium of European and US OA experts was held within the framework of the Annual European Congress of Rheumatology to discuss and compare guidelines and recommendations for the treatment of knee OA and to reach a consensus for management, particularly for areas in which there is no clear consensus: non-pharmacological therapy; efficacy and safety of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs); intra-articular (i.a.) hyaluronates (HA); and the role of chondroitin sulfate (CS) and/or glucosamine sulfate (GS).

RESULTS

All guidelines reviewed agree that knee OA is a progressive disease of the joint whose management requires non-pharmacological and pharmacological approaches. Discrepancies between guidelines are few and mostly reflect heterogeneity of expert panels involved, geographical differences in the availability of pharmacotherapies, and heterogeneity of the studies included. Panels chosen for guideline development should include experts with real clinical experience in drug use and patient management. Implementation of agreed guidelines can be thwarted by drug availability and reimbursement plans, resulting in optimal OA treatment being jeopardized, HA and symptomatic slow-acting drugs for osteoarthritis (SySADOAs) being clear examples of drugs whose availability and prescription can greatly vary geographically. In addition, primary care providers, often responsible for OA management (at least in early disease), may not adhere to clinical care guidelines, particularly for non-pharmacological OA treatment.

CONCLUSION

Harmonization of the recommendations for knee OA treatment is challenging but feasible, as shown by the step-by-step therapeutic algorithm developed by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). More easily disseminated and implemented guidance for OA treatment in the primary care setting is key to improved management of OA.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 616132 Genoa, Italy. Electronic address: mcutolo@unige.it.

    ,

    Department of Rheumatology, Faculty of Medicine Pierre & Marie Curie Paris VI, Saint-Antoine Hospital, AP-HP, Paris, France.

    ,

    Department of Medicine and Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

    ,

    Department of Medicine DIMED, University of Padua, Padua, Italy.

    Department of Public Health Sciences, State University of Liège, Liège, Belgium.

    Source

    MeSH

    Anti-Inflammatory Agents, Non-Steroidal
    Braces
    Chondroitin Sulfates
    Exercise Therapy
    Foot Orthoses
    Glucosamine
    Humans
    Hyaluronic Acid
    Injections, Intra-Articular
    Osteoarthritis, Knee
    Practice Guidelines as Topic
    Viscosupplements
    Weight Loss

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    25677861

    Citation

    Cutolo, Maurizio, et al. "Commentary On Recent Therapeutic Guidelines for Osteoarthritis." Seminars in Arthritis and Rheumatism, vol. 44, no. 6, 2015, pp. 611-7.
    Cutolo M, Berenbaum F, Hochberg M, et al. Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum. 2015;44(6):611-7.
    Cutolo, M., Berenbaum, F., Hochberg, M., Punzi, L., & Reginster, J. Y. (2015). Commentary on recent therapeutic guidelines for osteoarthritis. Seminars in Arthritis and Rheumatism, 44(6), pp. 611-7. doi:10.1016/j.semarthrit.2014.12.003.
    Cutolo M, et al. Commentary On Recent Therapeutic Guidelines for Osteoarthritis. Semin Arthritis Rheum. 2015;44(6):611-7. PubMed PMID: 25677861.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Commentary on recent therapeutic guidelines for osteoarthritis. AU - Cutolo,Maurizio, AU - Berenbaum,Francis, AU - Hochberg,Marc, AU - Punzi,Leonardo, AU - Reginster,Jean-Yves, Y1 - 2014/12/24/ PY - 2014/10/01/received PY - 2014/11/19/revised PY - 2014/12/19/accepted PY - 2015/2/14/entrez PY - 2015/2/14/pubmed PY - 2016/4/15/medline KW - Chondroitin sulfate KW - Glucosamine KW - Guidelines KW - Hyaluronates KW - NSAIDs KW - Osteoarthritis treatment SP - 611 EP - 7 JF - Seminars in arthritis and rheumatism JO - Semin. Arthritis Rheum. VL - 44 IS - 6 N2 - BACKGROUND: Despite availability of international evidence-based guidelines for osteoarthritis (OA) management, agreement on the different treatment modalities is lacking. METHOD: A symposium of European and US OA experts was held within the framework of the Annual European Congress of Rheumatology to discuss and compare guidelines and recommendations for the treatment of knee OA and to reach a consensus for management, particularly for areas in which there is no clear consensus: non-pharmacological therapy; efficacy and safety of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs); intra-articular (i.a.) hyaluronates (HA); and the role of chondroitin sulfate (CS) and/or glucosamine sulfate (GS). RESULTS: All guidelines reviewed agree that knee OA is a progressive disease of the joint whose management requires non-pharmacological and pharmacological approaches. Discrepancies between guidelines are few and mostly reflect heterogeneity of expert panels involved, geographical differences in the availability of pharmacotherapies, and heterogeneity of the studies included. Panels chosen for guideline development should include experts with real clinical experience in drug use and patient management. Implementation of agreed guidelines can be thwarted by drug availability and reimbursement plans, resulting in optimal OA treatment being jeopardized, HA and symptomatic slow-acting drugs for osteoarthritis (SySADOAs) being clear examples of drugs whose availability and prescription can greatly vary geographically. In addition, primary care providers, often responsible for OA management (at least in early disease), may not adhere to clinical care guidelines, particularly for non-pharmacological OA treatment. CONCLUSION: Harmonization of the recommendations for knee OA treatment is challenging but feasible, as shown by the step-by-step therapeutic algorithm developed by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). More easily disseminated and implemented guidance for OA treatment in the primary care setting is key to improved management of OA. SN - 1532-866X UR - https://www.unboundmedicine.com/medline/citation/25677861/Commentary_on_recent_therapeutic_guidelines_for_osteoarthritis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0049-0172(14)00326-6 DB - PRIME DP - Unbound Medicine ER -